Press Releases
Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target
Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty-driven pharmaceutical company, announced today that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase...
Press Releases
World Pharma Today: Goose Bags Strides Arcolab, Indoco Remedies and Macleods ‘Track & Trace’ Deals
Goose Leads Track & Trace Solutions Pack; New Customer wins gives booster to market confidenceHyderabad, India, Hyderabad based Goose  (www.goose.co.in) indigenously developed B2B Track and Trace solution Tracker aimed at helping pharma companies detect counterfeit drugs and protect their...
Press Releases
Fluxion Biosciences Launches the F1 Giga-Ohm Seal Plates for the IonFlux System
Fluxion Biosciences announced that it has introduced F1 giga-ohm seal plates for the IonFlux automated patch clamp system. The newly launched F1 plates complement Fluxion’s existing 20-cell ensemble recording plates and are fully compatible with all IonFlux systems. Users...
Press Releases
Cytheris announces interim results from ECLIPSE II Hepatitis C multicenter study of IL-7 in chronically infected genotype one and four nonresponders to standard of...
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE II Phase I/IIa study indicate that treatment with four weeks...
Press Releases
FDA Approves ERBITUX for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
Eli Lilly and Company and Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved ERBITUX® (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous...
Press Releases
Trophos initiates phase II proof of concept study for novel cardioprotective compound, TRO40303, in acute myocardial infarction
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today that the first patient has been treated in a phase II proof-of-concept study...
Press Releases
Hybrigenics’ specific inhibitor of Ubiquitin-Specific Protease 7 (USP7) is cytotoxic for chronic lymphocytic leukaemia (CLL) cells in vitro
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the presentation by Professor Tatjana Stankovic, from the University of Birmingham (UK) School...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.